調剤薬局市場規模、シェア、動向、2030年までの世界予測

調剤薬局市場 – 製品（経口、局所、非経口）、配合タイプ（成分変更、投与量変更）、治療用途（疼痛管理、HRT）、無菌性（無菌）、エンドユーザー（小児、成人） – 2030年までの世界予測

世界の調剤薬局市場は、2025年の推定147億2,000万米ドルから2030年には194億1,000万米ドルに達すると予測されており、2025年から2030年にかけて5.7%の年平均成長率（CAGR）で成長が見込まれています。市場の成長は、主に個別化投薬へのトレンドの高まりによって牽引されてきました。しかしながら、API、添加剤の供給、CCI/試験におけるキャパシティ制約が市場の成長を阻害すると予想されます。

本調査レポートは、調剤薬局市場を製品（経口、外用、非経口）、調剤タイプ（成分変更、用量変更）、治療適用（疼痛管理、ホルモン補充療法）、無菌性（無菌）、エンドユーザー（小児、成人）別に分類しています。レポートでは、調剤薬局市場の成長に影響を与える主要要因（促進要因、抑制要因、課題、機会など）に関する詳細な情報を提供しています。また、主要業界プレーヤーの詳細な分析も掲載し、事業概要、製品、ソリューション、戦略、協業、パートナーシップ、契約に関する洞察を提供しています。さらに、新規承認、発売、協業、買収など、調剤薬局市場に関連する最近の動向も網羅しています。

本レポートは、調剤薬局市場全体とそのサブセグメントの収益に関する最も正確な推定値を提供することで、市場リーダー企業と新規参入企業を支援します。また、ステークホルダーが競争環境をより深く理解し、事業を効果的にポジショニングし、適切な市場開拓戦略を策定するための洞察を深めるのに役立ちます。本レポートは、ステークホルダーが市場の主要指標を把握し、主要な市場牽引要因、制約要因、機会、課題に関する情報を提供することを可能にします。

Report Description

The global compounding pharmacy market is projected to reach USD 19.41 billion by 2030 from an estimated USD 14.72 billion in 2025, at a CAGR of 5.7% from 2025 to 2030. The market’s growth has mainly been driven by the increasing trend toward personalized doses. However, capacity constraints in API, excipient supply, and CCI/testing are expected to limit the market.

The oral drugs held the highest share in the compounding pharmacy market by product type.

The compounding pharmacy market is segmented by product type into topical drugs, oral drugs, parenteral drugs, rectal drugs, nasal drugs, ophthalmic drugs, and other products. Among these, the oral drugs segment holds a key position in the global market, driven by the increasing need for personalized therapies tailored to individual patient requirements. This segment includes a wide variety of formulations such as capsules, tablets, lozenges, solutions, and suspensions, which are extensively used in hormone replacement therapy, pediatric and geriatric care, pain management, gastrointestinal treatments, and chronic disease management. Compounded oral medications enable pharmacists to customize dosage strengths, flavors, excipients, and release profiles, thereby improving patient compliance—especially among those who have difficulty swallowing standard tablets or who need precise dosing. The rising prevalence of chronic conditions like cardiovascular diseases, diabetes, and endocrine disorders further fuels this segment’s growth by creating demand for personalized oral treatments that maximize efficacy and reduce side effects. Technological innovations, including sustained-release systems, taste-masking techniques, and bioavailability-enhancing carriers, improve therapeutic performance and patient experience. Adherence to FDA regulations and USP standards ensures safety, sterility, and quality, building confidence among healthcare providers and patients. Along with the growing emphasis on personalized medicine and increased availability through hospitals, specialty clinics, and retail pharmacies, oral drugs continue to be a major driver of revenue growth. The segment’s focus on convenience, customization, and effective therapy highlights its vital role in the overall development of the global compounding pharmacy market.

The pain management segment reported the highest share of the therapeutic application segment in 2024

The pain management segment holds the largest share in the pharmaceutical market by therapeutic application, driven by the global prevalence of acute and chronic pain conditions across musculoskeletal, neuropathic, and post-surgical patient groups. Increasing cases of arthritis, back pain, cancer-related pain, and migraines have boosted demand for effective pain relief therapies, including NSAIDs, opioids, topical analgesics, and combination treatments. The rising use of personalized pain management options, such as sustained-release formulations and targeted delivery systems, improves effectiveness while reducing systemic side effects, further increasing patient adherence and market growth. Technological advances, like transdermal patches and localized injectable therapies, have broadened treatment choices and made long-term pain management more convenient for patients. Favorable insurance coverage, greater awareness of pain as a key health issue, and the expanding elderly population support consistent growth in this segment. Leading pharmaceutical firms are enhancing their portfolios through research into new analgesics, biologics, and non-opioid alternatives, positioning themselves to capture larger market shares. As the need for safe, effective, and patient-focused pain management solutions continues to grow, this therapeutic segment is expected to stay dominant, reflecting sustained revenue increases and ongoing innovation in both developed and emerging markets.

North America accounted for the largest market share in the global Compounding pharmacy market from 2025 to 2030.

North America remains the leading region in the global compounding pharmacy market, mainly due to the United States. The region’s dominance is linked to its strong healthcare infrastructure, strict regulatory standards, and a large presence of both 503A and 503B compounding pharmacies. These pharmacies are essential in providing personalized medications, especially where commercially available drugs are insufficient. The US market offers a wide variety of compounded products, including oral, topical, and sterile preparations, to meet different therapeutic needs. Recent trends show a rising demand for specialized compounded medications, particularly in pain management, hormone replacement therapy, and pediatric care. Regulatory agencies like the FDA continue to monitor and ensure the safety and effectiveness of compounded drugs, building trust within the healthcare system. This combination of factors highlights North America’s key role in advancing and improving access to compounding pharmacy services.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side-70% and Demand Side-30%
• By Designation: Managers-45%, CXO and Directors-30%, and Executives-25%
• By Region: North America-40%, Europe-25%, the Asia Pacific-25%, Latin America-5%, and the Middle East & Africa-5%

List of Key Companies Profiled in the Report:

Key players in the Compounding pharmacy  market include Baxter (US), Empower Pharmacy (US), B. Braun (Germany), Fagron (Netherlands), QuVa Pharma (US), SCA Pharma (US), Nephron Pharmaceuticals (US), Leiters Health (US), Pharmaxo (UK), Icon Group (Australia), Roseway Labs (UK), ITH Pharma (UK), Pencol Compounding Pharmacy (Canada), Formula 8 (South Africa), and Aurora Compounding Pharmacy (Canada)

Research Coverage:

This research report categorizes the compounding pharmacy market by product (oral, topical, parenteral), compounding type (ingredient alteration, dosage alteration), therapeutic application (pain management, HRT), sterility (sterile), and end user (pediatric, adult). The scope of the report includes detailed information about the main factors affecting the growth of the Compounding pharmacy market, such as drivers, restraints, challenges, and opportunities. It also features an in-depth analysis of key industry players, offering insights into their business overview, products, solutions, strategies, collaborations, partnerships, and agreements. The report covers recent developments like new approvals, launches, collaborations, acquisitions, and other updates related to the Compounding pharmacy market.

Key Benefits of Buying the Report:

The report will assist market leaders and new entrants by providing them with the closest estimates of revenue figures for the entire Compounding pharmacy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop appropriate go-to-market strategies. This report will enable stakeholders to grasp the market’s key indicators and offer information on the main market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (Persistent drug shortages in North America and Europe, full enforcement of USP standards, safety push for ready-to-administer and standardized doses, continued demand creating supply gap for GLP-1 drugs, and trend toward personalization of doses), restraints (Resolution of GLP-1 shortages reduces reliance on compounded alternatives, stricter FDA oversight and insanitary conditions enforcement, and limitations on bulk drug substances.), opportunities (Expansion of hospital outsourcing into anesthesia, critical care, ophthalmic & chemo-adjuncts and Radiopharmaceutical compounding standardization), and challenges (Capacity bottlenecks in API, excipient supply, and CCI/testing, and limited quality-system maturity and gaps in stability/BUD evidence generation.) influencing the growth of the market.

• Service Development/Innovation: Detailed insights on upcoming technologies, research & development activities in the compounding pharmacy market
• Market Development: Comprehensive information about lucrative markets – the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the compounding pharmacy market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the Compounding pharmacy market.

Table of Contents

1               INTRODUCTION              31

1.1           STUDY OBJECTIVES       31

1.2           MARKET DEFINITION   31

1.3           STUDY SCOPE   32

1.3.1        MARKET SEGMENTATION & REGIONAL SCOPE 32

1.3.2        INCLUSIONS & EXCLUSIONS       33

1.3.3        YEARS CONSIDERED      33

1.3.4        CURRENCY CONSIDERED            34

1.4           STAKEHOLDERS               34

2               RESEARCH METHODOLOGY       35

2.1           RESEARCH DATA              35

2.1.1        SECONDARY DATA          36

2.1.1.1    Objectives of secondary research       36

2.1.1.2    Key data from secondary sources       37

2.1.2        PRIMARY DATA 37

2.1.2.1    Breakdown of primaries (supply- and demand-side participants)                 38

2.1.2.2    Key objectives of primary research    38

2.2           MARKET SIZE ESTIMATION         39

2.2.1        GLOBAL MARKET ESTIMATION 39

2.2.1.1    Company revenue analysis (bottom-up approach)         39

2.2.1.2    Revenue share analysis        40

2.2.1.3    MnM repository analysis     41

2.2.1.4    Primary interviews                41

2.2.2        INSIGHTS OF PRIMARY EXPERTS              41

2.2.3        SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)       42

2.3           MARKET GROWTH RATE PROJECTIONS                43

2.4           DATA TRIANGULATION                45

2.5           STUDY ASSUMPTIONS  46

2.6           RESEARCH LIMITATIONS             47

2.7           RISK ANALYSIS  47

3               EXECUTIVE SUMMARY  48

3.1           SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST                48

3.2           STRATEGIC IMPERATIVES FOR KEY STAKEHOLDERS                 49

3.2.1        STARTUPS AND INNOVATIVE COMPANIES          49

3.2.2        ESTABLISHED MARKET LEADERS             49

4               PREMIUM INSIGHTS       54

4.1           COMPOUNDING PHARMACY MARKET OVERVIEW                 54

4.2           NORTH AMERICA: COMPOUNDING PHARMACY MARKET, BY PRODUCT AND COUNTRY (2025)   55

4.3           COMPOUNDING PHARMACY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES         56

4.4           COMPOUNDING PHARMACY MARKET: EMERGING VS. DEVELOPED MARKETS 57

4.5           INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES              57

4.6           EMERGING BUSINESS MODELS & ECOSYSTEM SHIFTS                 58

4.7           VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE       58

4.8           REGULATORY POLICY INITIATIVES        59

5               MARKET OVERVIEW       60

5.1           INTRODUCTION              60

5.2           MARKET DYNAMICS       60

5.2.1        DRIVERS               61

5.2.1.1    Persistent drug shortages in North America and Europe                 61

5.2.1.2    Enforcement of USP standards          62

5.2.1.3    Push for ready-to-administer (RTA) and standardized doses                 62

5.2.1.4    Continued demand-supply gap for GLP-1 drugs            63

5.2.1.5    Trend towards personalization of doses            63

5.2.2        RESTRAINTS      64

5.2.2.1    Resolution of GLP-1 shortages and reduced reliance on compounded alternatives    64

5.2.2.2    Stricter FDA oversight and intensified enforcement of unsanitary conditions violations            64

5.2.2.3    Limitations on bulk drug substances 64

5.2.3        OPPORTUNITIES              65

5.2.3.1    Expansion of hospital outsourcing into anesthesia, critical care, ophthalmic, and chemo-adjuncts       65

5.2.3.2    Radiopharmaceutical compounding standardization      65

5.2.4        CHALLENGES    66

5.2.4.1    Capacity bottlenecks in API, excipient supply, and critical compounding infrastructure testing  66

5.2.4.2    Limited quality-system maturity and gaps in stability/BUD evidence generation              66

5.3           PORTER’S FIVE FORCES ANALYSIS           67

5.3.1        THREAT OF NEW ENTRANTS      68

5.3.2        THREAT OF SUBSTITUTES          68

5.3.3        BARGAINING POWER OF SUPPLIERS       68

5.3.4        BARGAINING POWER OF BUYERS             68

5.3.5        INTENSITY OF COMPETITIVE RIVALRY 69

5.4           KEY STAKEHOLDERS & BUYING CRITERIA            69

5.4.1        KEY STAKEHOLDERS IN BUYING PROCESS           69

5.4.2        KEY BUYING CRITERIA  71

5.5           MACROECONOMICS INDICATORS           72

5.5.1        HEALTHCARE EXPENDITURE TRENDS  72

5.5.2        GLOBAL CANCER BURDEN          73

5.5.3        IMPACT OF PHARMA R&D            74

5.6           VALUE CHAIN ANALYSIS               75

5.7           ECOSYSTEM ANALYSIS  77

5.7.1        ROLE IN ECOSYSTEM     78

5.8           PRICING ANALYSIS          79

5.8.1        INDICATIVE PRICING ANALYSIS OF COMPOUNDING PHARMACY PRODUCTS, BY KEY PLAYER, 2024    79

5.8.2        INDICATIVE PRICING ANAYLSIS OF COMPOUNDING PHARMACY PRODUCTS, BY REGION, 2024             80

5.9           KEY CONFERENCES & EVENTS, 2025–2026              80

5.10         TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES       81

5.11         INVESTMENT & FUNDING SCENARIO     82

5.12         TECHNOLOGY ANALYSIS             83

5.12.1      KEY TECHNOLOGIES     83

5.12.1.1  Automated compounding devices      83

5.12.1.2  Sterile compounding equipment        83

5.12.2      COMPLEMENTARY TECHNOLOGIES       84

5.12.2.1  Quality control & testing systems      84

5.12.2.2  Pharmacy information management software (PIMS)  84

5.12.3      ADJACENT TECHNOLOGIES       84

5.12.3.1  3D printing of pharmaceuticals          84

5.12.3.2  Personalized medicine platforms       85

5.13         IMPACT OF AI/GEN AI ON COMPOUNDING PHARMACY MARKET               85

5.14         REGULATORY ANALYSIS               86

5.14.1      REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS, BY REGION   86

5.14.2      REGULATORY FRAMEWORK       89

5.15         IMPACT OF 2025 US TARIFF ON COMPOUNDING PHARMACY MARKET      92

5.15.1      INTRODUCTION              92

5.15.2      KEY TARIFF RATES          93

5.15.3      PRICE IMPACT ANALYSIS             94

5.15.4      IMPACT ON COUNTRY/REGION                94

5.15.4.1  US           94

5.15.4.2  Europe   95

5.15.4.3  Asia Pacific            95

5.15.4.4  Rest of the World 96

5.15.5      IMPACT ON MANUFACTURING INDUSTRIES      96

5.16         UNMET NEEDS & WHITE SPACES              97

6               COMPOUNDING PHARMACY MARKET, BY PRODUCT                 98

6.1           INTRODUCTION              99

6.2           ORAL DRUGS     99

6.2.1        INCREASING DEMAND FOR PRECISE AND CUSTOMIZABLE ORAL FORMULATIONS IN UNMET PATIENT POPULATIONS TO DRIVE MARKET          99

6.3           TOPICAL DRUGS              102

6.3.1        RISING DEMAND FOR PERSONALIZED TOPICAL TREATMENTS AND ADVANCED DELIVERY VEHICLES TO FUEL MARKET GROWTH          102

6.4           PARENTERAL DRUGS     105

6.4.1        RISING DEMAND FOR STERILE INJECTABLE THERAPIES AND SUPPLY-CHAIN DISRUPTIONS TO BOOST MARKET GROWTH             105

6.5           OPTHALMIC DRUGS       108

6.5.1        RISING CASES OF EYE-RELATED DISORDERS TO ACCELERATE MARKET GROWTH              108

6.6           NASAL DRUGS   111

6.6.1        ADVANCEMENTS IN NASAL DRUG DELIVERY SYSTEMS AND FAVORABLE REGULATORY POLICIES TO PROPEL MARKET GROWTH             111

6.7           RECTAL DRUGS                114

6.7.1        PERSONALIZED FORMULATIONS AND REGULATORY SUPPORT TO DRIVE GROWTH IN RECTAL COMPOUNDING THERAPIES         114

6.8           OTHER PRODUCTS         117

7               COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE  121

7.1           INTRODUCTION              122

7.2           PHARMACEUTICAL DOSAGE ALTERATION          122

7.2.1        TAILORED DOSAGE FORMS TO ENHANCE PATIENT ADHERENCE AND CUSTOMIZATION IN COMPOUNDED MEDICATIONS  122

7.3           PHARMACEUTICAL INGREDIENTS ALTERATION                 125

7.3.1        INCREASED NEED FOR CUSTOMIZED PHARMACEUTICAL INGREDIENTS TO ENHANCE PATIENT-CENTRIC COMPOUNDING SOLUTIONS 125

7.4           CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING          128

7.4.1        PERSISTENT GLOBAL DRUG SHORTAGES AND LIMITATIONS OF LARGE-SCALE PHARMACEUTICAL PRODUCTION TO PROPEL ADOPTION 128

8               COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION    132

8.1           INTRODUCTION              133

8.2           PAIN MANAGEMENT      133

8.2.1        NEED FOR PERSONALIZED PAIN RELIEF SOLUTIONS FOR CHRONIC AILMENTS TO SUPPORT MARKET              133

8.3           HORMONE REPLACEMENT THERAPIES 136

8.3.1        POPULARITY OF PERSONALIZED HORMONE THERAPIES TO DRIVE STEADY GROWTH IN GLOBAL COMPOUNDING PHARMACY MARKET   136

8.4           DERMAL DISORDERS     139

8.4.1        CUSTOMIZED DERMATOLOGICAL SOLUTIONS TO PROPEL GLOBAL COMPOUNDING PHARMACY MARKET EXPANSION        139

8.5           NUTRITIONAL SUPPLEMENTS  142

8.5.1        PERSONALIZED NUTRACEUTICALS TO OFFER NICHE BUT BETTER GROWTH OPPORTUNITIES IN COMPOUNDING PHARMACIES     142

8.6           OTHER THERAPEUTIC APPLICATIONS  145

9               COMPOUNDING PHARMACY MARKET, BY STERILITY                 149

9.1           INTRODUCTION              150

9.2           STERILE                150

9.2.1        RTU/RTA STERILE PREPARATIONS AND OPHTHALMIC PACKS TO DRIVE RAPID GROWTH IN COMPOUNDING PHARMACIES     150

9.3           NON-STERILE    153

9.3.1        503A/MAGISTRAL NON-STERILE PREPARATIONS TO DRIVE GLOBAL VOLUME AND VALUE LEADERSHIP IN COMPOUNDING PHARMACIES  153

10            COMPOUNDING PHARMACY MARKET, BY END USER                 157

10.1         INTRODUCTION              158

10.2         ADULTS                158

10.2.1      RISING CHRONIC DISEASE BURDEN AND PERSONALIZED THERAPIES TO AUGMENT ADULT SEGMENT GROWTH             158

10.3         GERIATRIC PATIENTS   161

10.3.1      AGING DEMOGRAPHICS AND DOSE-FORM CUSTOMIZATION TO PROPEL GERIATRIC SEGMENT GROWTH                 161

10.4         PEDIATRIC PATIENTS   164

10.4.1      CUSTOMIZED DOSAGE FORMS AND PEDIATRIC-SPECIFIC NEEDS TO DRIVE GROWTH     164

11            COMPOUNDING PHARMACY MARKET, BY REGION                 168

11.1         INTRODUCTION              169

11.2         NORTH AMERICA             170

11.2.1      MACROECONOMIC OUTLOOK FOR NORTH AMERICA                 171

11.2.2      US           174

11.2.2.1  US to dominate North American compounding pharmacy market during forecast period          174

11.2.3      CANADA               177

11.2.3.1  Personalized treatments, regulatory reinforcement, and supply-gap filling to fuel global compounding pharmacy growth               177

11.3         EUROPE               180

11.3.1      MACROECONOMIC OUTLOOK FOR EUROPE      180

11.3.2      GERMANY           184

11.3.2.1  Aging demographics, technological advancements, and supportive regulations to drive market              184

11.3.3      UK          186

11.3.3.1  Personalized treatments, chronic disease management, and regulatory support to support market growth  186

11.3.4      FRANCE                189

11.3.4.1  Focus on chronic disease management to fuel growth in French compounding pharmacy market         189

11.3.5      ITALY    191

11.3.5.1  Rising commercial drug development pipeline to spur market growth    191

11.3.6      SPAIN    194

11.3.6.1  Global regulatory advancements and rising R&D activities to drive market          194

11.3.7      REST OF EUROPE             196

11.4         ASIA PACIFIC     199

11.4.1      MACROECONOMIC OUTLOOK FOR ASIA PACIFIC                 200

11.4.2      CHINA  204

11.4.2.1  Low manufacturing cost and high demand for medicines to favor market growth       204

11.4.3      JAPAN   206

11.4.3.1  Increasing prevalence of chronic diseases and growing geriatric population to fuel demand for customized medications 206

11.4.4      INDIA    209

11.4.4.1  Increasing pharma R&D activities to support market growth                 209

11.4.5      AUSTRALIA         211

11.4.5.1  Innovation in clinical practice and regulatory support to accelerate compounding pharmacy growth      211

11.4.6      SOUTH KOREA  213

11.4.6.1  Regulatory innovation and automation to fuel South Korean compounding pharmacy market growth            213

11.4.7      REST OF ASIA PACIFIC   216

11.5         LATIN AMERICA                219

11.5.1      MACROECONOMIC OUTLOOK FOR LATIN AMERICA                 219

11.5.2      BRAZIL 222

11.5.2.1  Growing pharmacy & biologics manufacturing sectors and rising R&D sepnding to drive market           222

11.5.3      MEXICO                225

11.5.3.1  Regulatory improvements, high cancer rates, and robust pharmaceutical industry to boost market growth             225

11.5.4      REST OF LATIN AMERICA             227

11.6         MIDDLE EAST & AFRICA                230

11.6.1      MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 230

11.6.2      GCC COUNTRIES              234

11.6.2.1  Rising demand for biologics and increasing prevalence of non-communicable diseases to propel market growth            234

11.6.3      REST OF MIDDLE EAST & AFRICA             237

12            COMPETITIVE LANDSCAPE         241

12.1         INTRODUCTION              241

12.2         KEY PLAYER STRATEGIES/RIGHT TO WIN            241

12.2.1      OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN COMPOUNDING PHARMACY MARKET, 2023−2025      241

12.3         REVENUE ANALYSIS, 2022–2024  243

12.4         MARKET SHARE ANALYSIS, 2024                 244

12.5         COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024                 246

12.5.1      STARS   246

12.5.2      EMERGING LEADERS     246

12.5.3      PERVASIVE PLAYERS      246

12.5.4      PARTICIPANTS 246

12.5.5      COMPETITIVE BENCHMARKING: KEY PLAYERS, 2024                 248

12.5.5.1  Company footprint               248

12.5.5.2  Region footprint   248

12.5.5.3  Product footprint  249

12.5.5.4  Therapeutic application footprint      250

12.5.5.5  Sterility footprint  250

12.6         COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024        251

12.6.1      PROGRESSIVE COMPANIES         251

12.6.2      RESPONSIVE COMPANIES            251

12.6.3      DYNAMIC COMPANIES  251

12.6.4      STARTING BLOCKS         251

12.6.5      COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024                 253

12.6.5.1  Detailed list of key startup/SMEs      253

12.6.5.2  Competitive benchmarking of key startups/SMEs          254

12.7         COMPANY VALUATION & FINANCIAL METRICS 255

12.7.1      FINANCIAL METRICS      255

12.7.2      COMPANY VALUATION 255

12.8         BRAND/PRODUCT COMPARISON             256

12.9         COMPETITIVE SCENARIO             257

12.9.1      PRODUCT LAUNCHES   257

12.9.2      DEALS  258

12.9.3      EXPANSIONS     259

13            COMPANY PROFILES      260

13.1         KEY PLAYERS     260

13.1.1      BAXTER                260

13.1.1.1  Business overview 260

13.1.1.2  Products offered   261

13.1.1.3  Recent developments           262

13.1.1.3.1                Product launches  262

13.1.1.4  MnM view              262

13.1.1.4.1                Key strengths        262

13.1.1.4.2                Strategic choices   262

13.1.1.4.3                Weaknesses & competitive threats     262

13.1.2      EMPOWER PHARMACY  263

13.1.2.1  Business overview 263

13.1.2.2  Products offered   263

13.1.2.3  Recent developments           265

13.1.2.3.1                Expansions             265

13.1.2.4  MnM view              265

13.1.2.4.1                Key strengths        265

13.1.2.4.2                Strategic choices   265

13.1.2.4.3                Weaknesses & competitive threats     265

13.1.3      B. BRAUN SE       266

13.1.3.1  Business overview 266

13.1.3.2  Products offered   267

13.1.3.3  Recent developments           268

13.1.3.3.1                Product launches  268

13.1.3.4  MnM view              268

13.1.3.4.1                Key strengths        268

13.1.3.4.2                Strategic choices   268

13.1.3.4.3                Weaknesses & competitive threats     268

13.1.4      FAGRON               269

13.1.4.1  Business overview 269

13.1.4.2  Products offered   270

13.1.4.3  Recent developments           271

13.1.4.3.1                Deals      271

13.1.4.4  MnM view              271

13.1.4.4.1                Key strengths        271

13.1.4.4.2                Strategic choices   271

13.1.4.4.3                Weaknesses & competitive threats     272

13.1.5      QUVA PHARMA, INC.      273

13.1.5.1  Business overview 273

13.1.5.2  Products offered   273

13.1.5.3  MnM view              274

13.1.5.3.1                Key strengths        274

13.1.5.3.2                Strategic choices   274

13.1.5.3.3                Weaknesses & competitive threats     275

13.1.6      SCA PHARMA     276

13.1.6.1  Business overview 276

13.1.6.2  Products offered   276

13.1.6.3  Recent developments           277

13.1.6.3.1                Deals      277

13.1.7      NEPHRON PHARMACEUTICALS 278

13.1.7.1  Business overview 278

13.1.7.2  Products offered   278

13.1.7.3  Recent developments           279

13.1.7.3.1                Expansions             279

13.1.8      LEITERS HEALTH             280

13.1.8.1  Business overview 280

13.1.8.2  Products offered   280

13.1.8.3  Recent developments           281

13.1.8.3.1                Expansions             281

13.1.9      ICON GROUP     282

13.1.9.1  Business overview 282

13.1.9.2  Products offered   282

13.1.9.3  Recent developments           283

13.1.9.3.1                Deals      283

13.1.10   ROSEWAY LABS 284

13.1.10.1                 Business overview 284

13.1.10.2                 Products offered   284

13.1.10.3                 Recent developments           285

13.1.10.3.1             Other developments             285

13.1.11   ITH PHARMA     286

13.1.11.1                 Business overview 286

13.1.11.2                 Products offered   286

13.1.12   PENCOL COMPOUNDING PHARMACY   287

13.1.12.1                 Business overview 287

13.1.12.2                 Products offered   287

13.1.13   FORMUL8            288

13.1.13.1                 Business overview 288

13.1.13.2                 Products offered   288

13.1.14   AURORA COMPOUNDING PHARMACY   289

13.1.14.1                 Business overview 289

13.1.14.2                 Products offered   289

13.2         OTHER PLAYERS              290

13.2.1      CUSTOM MED APOTHECARY     290

13.2.2      INSTITUTIONAL PHARMACY SOLUTIONS            291

13.2.3      FUSION APOTHECARY  291

13.2.4      INNOVATION COMPOUNDING PHARMACY         292

13.2.5      RX3 COMPOUNDING PHARMACY              292

13.2.6      DOUGHERTY’S PHARMACY, INC.              293

13.2.7      LORRAINE’S PHARMACY               293

13.2.8      WELLS PHARMA                294

13.2.9      OLYMPIA PHARMACY    294

13.2.10   FRESH THERAPEUTICS 295

13.2.11   MEDIOS AG        296

14            APPENDIX           297

14.1         DISCUSSION GUIDE        297

14.2         KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL                301

14.3         CUSTOMIZATION OPTIONS        303

14.4         RELATED REPORTS         303

14.5         AUTHOR DETAILS           304

LIST OF TABLES

TABLE 1                COMPOUNDING PHARMACY MARKET: INCLUSIONS & EXCLUSIONS       33

TABLE 2                IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS  44

TABLE 3                COMPOUNDING PHARMACY MARKET: RISK ANALYSIS            47

TABLE 4                COMPOUNDING PHARMACY MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS           61

TABLE 5                COMPOUNDING PHARMACY MARKET: PORTER’S FIVE FORCES 67

TABLE 6                INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF COMPOUNDING PHARMACY PRODUCTS (%)                 70

TABLE 7                KEY BUYING CRITERIA FOR COMPOUNDING PHARMACY PRODUCTS, BY END USER  71

TABLE 8                HEALTH EXPENDITURE AND FINANCING, 2015–2024 (% OF GDP)               72

TABLE 9                US: CANCER INCIDENCE, BY STATE (2024)                 74

TABLE 10              COMPOUNDING PHARMACY MARKET: ROLE IN ECOSYSTEM       78

TABLE 11              INDICATIVE PRICING ANALYSIS COMPOUNDING PHARMACY PRODUCTS,

BY KEY PLAYER, 2024      79

TABLE 12              INDICATIVE PRICING ANAYLSIS OF COMPOUNDING PHARMACY PRODUCTS,

BY REGION, 2024               80

TABLE 13              COMPOUNDING PHARMACY MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026     80

TABLE 14              NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 86

TABLE 15              EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS           87

TABLE 16              ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 88

TABLE 17              REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 88

TABLE 18              COUNTRY-WISE REGULATORY SCENARIO FOR COMPOUNDING PHARMACIES  89

TABLE 19              US-ADJUSTED RECIPROCAL TARIFF RATES                 93

TABLE 20              COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)     99

TABLE 21              COMPOUNDING PHARMACY MARKET FOR ORAL DRUGS, BY REGION,

2023–2030 (USD MILLION)            100

TABLE 22              NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR ORAL DRUGS,

BY COUNTRY, 2023–2030 (USD MILLION)               100

TABLE 23              EUROPE: COMPOUNDING PHARMACY MARKET FOR ORAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)                 101

TABLE 24              ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR ORAL DRUGS,

BY COUNTRY, 2023–2030 (USD MILLION)               101

TABLE 25              LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR ORAL DRUGS,

BY COUNTRY, 2023–2030 (USD MILLION)               102

TABLE 26              MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR ORAL DRUGS, BY REGION, 2023–2030 (USD MILLION) 102

TABLE 27              COMPOUNDING PHARMACY MARKET FOR TOPICAL DRUGS, BY REGION,

2023–2030 (USD MILLION)            103

TABLE 28              NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR TOPICAL DRUGS,

BY COUNTRY, 2023–2030 (USD MILLION)               103

TABLE 29              EUROPE: COMPOUNDING PHARMACY MARKET FOR TOPICAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)                 104

TABLE 30              ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR TOPICAL DRUGS,

BY COUNTRY, 2023–2030 (USD MILLION)               104

TABLE 31              LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR TOPICAL DRUGS,

BY COUNTRY, 2023–2030 (USD MILLION)               105

TABLE 32              MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR TOPICAL DRUGS, BY REGION, 2023–2030 (USD MILLION)       105

TABLE 33              COMPOUNDING PHARMACY MARKET FOR PARENTERAL DRUGS, BY REGION, 2023–2030 (USD MILLION)                 106

TABLE 34              NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR PARENTERAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION) 106

TABLE 35              EUROPE: COMPOUNDING PHARMACY MARKET FOR PARENTERAL DRUGS,

BY COUNTRY, 2023–2030 (USD MILLION)               107

TABLE 36              ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR PARENTERAL DRUGS,

BY COUNTRY, 2023–2030 (USD MILLION)               107

TABLE 37              LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR PARENTERAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION) 108

TABLE 38              MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR PARENTERAL DRUGS, BY REGION, 2023–2030 (USD MILLION)            108

TABLE 39              COMPOUNDING PHARMACY MARKET FOR OPHTHALMIC DRUGS, BY REGION, 2023–2030 (USD MILLION)                 109

TABLE 40              NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR OPHTHALMIC DRUGS, BY COUNTRY, 2023–2030 (USD MILLION) 109

TABLE 41              EUROPE: COMPOUNDING PHARMACY MARKET FOR OPHTHALMIC DRUGS,

BY COUNTRY, 2023–2030 (USD MILLION)               110

TABLE 42              ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR OPHTHALMIC DRUGS,

BY COUNTRY, 2023–2030 (USD MILLION)               110

TABLE 43              LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR OPHTHALMIC DRUGS, BY COUNTRY, 2023–2030 (USD MILLION) 111

TABLE 44              MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR OPHTHALMIC DRUGS, BY REGION, 2023–2030 (USD MILLION)            111

TABLE 45              COMPOUNDING PHARMACY MARKET FOR NASAL DRUGS, BY REGION,

2023–2030 (USD MILLION)            112

TABLE 46              NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR NASAL DRUGS,

BY COUNTRY, 2023–2030 (USD MILLION)               112

TABLE 47              EUROPE: COMPOUNDING PHARMACY MARKET FOR NASAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)                 113

TABLE 48              ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR NASAL DRUGS,

BY COUNTRY, 2023–2030 (USD MILLION)               113

TABLE 49              LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR NASAL DRUGS,

BY COUNTRY, 2023–2030 (USD MILLION)               114

TABLE 50              MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR NASAL DRUGS, BY REGION, 2023–2030 (USD MILLION) 114

TABLE 51              COMPOUNDING PHARMACY MARKET FOR RECTAL DRUGS, BY REGION,

2023–2030 (USD MILLION)            115

TABLE 52              NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR RECTAL DRUGS,

BY COUNTRY, 2023–2030 (USD MILLION)               115

TABLE 53              EUROPE: COMPOUNDING PHARMACY MARKET FOR RECTAL DRUGS, BY COUNTRY, 2023–2030 (USD MILLION)                 116

TABLE 54              ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR RECTAL DRUGS,

BY COUNTRY, 2023–2030 (USD MILLION)               116

TABLE 55              LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR RECTAL DRUGS,

BY COUNTRY, 2023–2030 (USD MILLION)               117

TABLE 56              MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR RECTAL DRUGS, BY REGION, 2023–2030 (USD MILLION)       117

TABLE 57              COMPOUNDING PHARMACY MARKET FOR OTHER PRODUCTS, BY REGION,

2023–2030 (USD MILLION)            118

TABLE 58              NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR OTHER PRODUCTS,

BY COUNTRY, 2023–2030 (USD MILLION)               118

TABLE 59              EUROPE: COMPOUNDING PHARMACY MARKET FOR OTHER PRODUCTS,

BY COUNTRY, 2023–2030 (USD MILLION)               119

TABLE 60              ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR OTHER PRODUCTS,

BY COUNTRY, 2023–2030 (USD MILLION)               119

TABLE 61              LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR OTHER PRODUCTS,

BY COUNTRY, 2023–2030 (USD MILLION)               120

TABLE 62              MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR OTHER PRODUCTS, BY REGION, 2023–2030 (USD MILLION)       120

TABLE 63              COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE,

2023–2030 (USD MILLION)            122

TABLE 64              COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL DOSAGE ALTERATION, BY REGION, 2023–2030 (USD MILLION)       123

TABLE 65              NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL DOSAGE ALTERATION, BY COUNTRY, 2023–2030 (USD MILLION)     123

TABLE 66              EUROPE: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL DOSAGE ALTERATION, BY COUNTRY, 2023–2030 (USD MILLION)            124

TABLE 67              ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL DOSAGE ALTERATION, BY COUNTRY, 2023–2030 (USD MILLION)     124

TABLE 68              LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL DOSAGE ALTERATION, BY COUNTRY, 2023–2030 (USD MILLION)     125

TABLE 69              MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL DOSAGE ALTERATION, BY REGION, 2023–2030 (USD MILLION)     125

TABLE 70              COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL INGREDIENT ALTERATION, BY REGION, 2023–2030 (USD MILLION)            126

TABLE 71              NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL INGREDIENT ALTERATION, BY COUNTRY, 2023–2030 (USD MILLION)               126

TABLE 72              EUROPE: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL INGREDIENT ALTERATION, BY COUNTRY, 2023–2030 (USD MILLION)     127

TABLE 73              ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL INGREDIENT ALTERATION, BY COUNTRY, 2023–2030 (USD MILLION)               127

TABLE 74              LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL INGREDIENT ALTERATION, BY COUNTRY, 2023–2030 (USD MILLION)               128

TABLE 75              MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR PHARMACEUTICAL INGREDIENT ALTERATION, BY REGION,

2023–2030 (USD MILLION)            128

TABLE 76              COMPOUNDING PHARMACY MARKET FOR CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING, BY REGION, 2023–2030 (USD MILLION)                 129

TABLE 77              NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING, BY COUNTRY,

2023–2030 (USD MILLION)            129

TABLE 78              EUROPE: COMPOUNDING PHARMACY MARKET FOR CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING, BY COUNTRY, 2023–2030 (USD MILLION)                 130

TABLE 79              ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING, BY COUNTRY, 2023–2030 (USD MILLION)                 130

TABLE 80              LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING, BY COUNTRY,

2023–2030 (USD MILLION)            131

TABLE 81              MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING, BY REGION,

2023–2030 (USD MILLION)            131

TABLE 82              COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION,

2023–2030 (USD MILLION)            133

TABLE 83              COMPOUNDING PHARMACY MARKET FOR PAIN MANAGEMENT, BY REGION,

2023–2030 (USD MILLION)            134

TABLE 84              NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2030 (USD MILLION) 134

TABLE 85              EUROPE: COMPOUNDING PHARMACY MARKET FOR PAIN MANAGEMENT,

BY COUNTRY, 2023–2030 (USD MILLION)               135

TABLE 86              ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR PAIN MANAGEMENT,

BY COUNTRY, 2023–2030 (USD MILLION)               135

TABLE 87              LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR PAIN MANAGEMENT,

BY COUNTRY, 2023–2030 (USD MILLION)               136

TABLE 88              MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR PAIN MANAGEMENT, BY REGION, 2023–2030 (USD MILLION)            136

TABLE 89              COMPOUNDING PHARMACY MARKET FOR HORMONE REPLACEMENT THERAPIES, BY REGION, 2023–2030 (USD MILLION) 137

TABLE 90              NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR HORMONE REPLACEMENT THERAPIES, BY COUNTRY, 2023–2030 (USD MILLION)     137

TABLE 91              EUROPE: COMPOUNDING PHARMACY MARKET FOR HORMONE REPLACEMENT THERAPIES, BY COUNTRY, 2023–2030 (USD MILLION)            138

TABLE 92              ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR HORMONE REPLACEMENT THERAPIES, BY COUNTRY, 2023–2030 (USD MILLION)     138

TABLE 93              LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR HORMONE REPLACEMENT THERAPIES, BY COUNTRY, 2023–2030 (USD MILLION)     139

TABLE 94              MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR HORMONE REPLACEMENT THERAPIES, BY REGION, 2023–2030 (USD MILLION)          139

TABLE 95              COMPOUNDING PHARMACY MARKET FOR DERMAL DISORDERS, BY REGION, 2023–2030 (USD MILLION)                 140

TABLE 96              NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR DERMAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 140

TABLE 97              EUROPE: COMPOUNDING PHARMACY MARKET FOR DERMAL DISORDERS,

BY COUNTRY, 2023–2030 (USD MILLION)               141

TABLE 98              ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR DERMAL DISORDERS,

BY COUNTRY, 2023–2030 (USD MILLION)               141

TABLE 99              LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR DERMAL DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 142

TABLE 100            MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR DERMAL DISORDERS, BY REGION, 2023–2030 (USD MILLION)            142

TABLE 101            COMPOUNDING PHARMACY MARKET FOR NUTRITIONAL SUPPLEMENTS,

BY REGION, 2023–2030 (USD MILLION)   143

TABLE 102            NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2023–2030 (USD MILLION)            143

TABLE 103            EUROPE: COMPOUNDING PHARMACY MARKET FOR NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2023–2030 (USD MILLION) 144

TABLE 104            ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2023–2030 (USD MILLION)            144

TABLE 105            LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2023–2030 (USD MILLION)            145

TABLE 106            MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR NUTRITIONAL SUPPLEMENTS, BY REGION, 2023–2030 (USD MILLION)          145

TABLE 107            COMPOUNDING PHARMACY MARKET FOR OTHER THERAPEUTIC APPLICATIONS,

BY REGION, 2023–2030 (USD MILLION)   146

TABLE 108            NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)     146

TABLE 109            EUROPE: COMPOUNDING PHARMACY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)       147

TABLE 110            ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)     147

TABLE 111            LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)     148

TABLE 112            MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)  148

TABLE 113            COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)     150

TABLE 114            STERILE COMPOUNDING PHARMACY MARKET, BY REGION,

2023–2030 (USD MILLION)            151

TABLE 115            NORTH AMERICA: STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 151

TABLE 116            EUROPE: STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            152

TABLE 117            ASIA PACIFIC: STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            152

TABLE 118            LATIN AMERICA: STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 153

TABLE 119            MIDDLE EAST & AFRICA: STERILE COMPOUNDING PHARMACY MARKET,

BY REGION, 2023–2030 (USD MILLION)   153

TABLE 120            NON-STERILE COMPOUNDING PHARMACY MARKET, BY REGION,

2023–2030 (USD MILLION)            154

TABLE 121            NORTH AMERICA: NON-STERILE COMPOUNDING PHARMACY MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               154

TABLE 122            EUROPE: NON-STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            155

TABLE 123            ASIA PACIFIC: NON-STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 155

TABLE 124            LATIN AMERICA: NON-STERILE COMPOUNDING PHARMACY MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 156

TABLE 125            MIDDLE EAST & AFRICA: NON-STERILE COMPOUNDING PHARMACY MARKET,

BY REGION, 2023–2030 (USD MILLION)   156

TABLE 126            COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)                158

TABLE 127            COMPOUNDING PHARMACY MARKET FOR ADULTS, BY REGION,

2023–2030 (USD MILLION)            159

TABLE 128            NORTH AMERICA: COMPOUNDING PHARMACY MARKET ADULTS, BY COUNTRY, 2023–2030 (USD MILLION)                 159

TABLE 129            EUROPE: COMPOUNDING PHARMACY MARKET FOR ADULTS, BY COUNTRY,

2023–2030 (USD MILLION)            160

TABLE 130            ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR ADULTS, BY COUNTRY, 2023–2030 (USD MILLION)                 160

TABLE 131            LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR ADULTS, BY COUNTRY, 2023–2030 (USD MILLION)                 161

TABLE 132            MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR ADULTS,

BY REGION, 2023–2030 (USD MILLION)   161

TABLE 133            COMPOUNDING PHARMACY MARKET FOR GERIATRIC PATIENTS, BY REGION, 2023–2030 (USD MILLION)                 162

TABLE 134            NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR GERIATRIC PATIENTS, BY COUNTRY, 2023–2030 (USD MILLION) 162

TABLE 135            EUROPE: COMPOUNDING PHARMACY MARKET FOR GERIATRIC PATIENTS,

BY COUNTRY, 2023–2030 (USD MILLION)               163

TABLE 136            ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR GERIATRIC PATIENTS,

BY COUNTRY, 2023–2030 (USD MILLION)               163

TABLE 137            LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR GERIATRIC PATIENTS, BY COUNTRY, 2023–2030 (USD MILLION) 164

TABLE 138            MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR GERIATRIC PATIENTS, BY REGION, 2023–2030 (USD MILLION)            164

TABLE 139            COMPOUNDING PHARMACY MARKET FOR PEDIATRIC PATIENTS, BY REGION, 2023–2030 (USD MILLION)                 165

TABLE 140            NORTH AMERICA: COMPOUNDING PHARMACY MARKET FOR PEDIATRIC PATIENTS, BY COUNTRY, 2023–2030 (USD MILLION) 165

TABLE 141            EUROPE: COMPOUNDING PHARMACY MARKET FOR PEDIATRIC PATIENTS,

BY COUNTRY, 2023–2030 (USD MILLION)               166

TABLE 142            ASIA PACIFIC: COMPOUNDING PHARMACY MARKET FOR PEDIATRIC PATIENTS,

BY COUNTRY, 2023–2030 (USD MILLION)               166

TABLE 143            LATIN AMERICA: COMPOUNDING PHARMACY MARKET FOR PEDIATRIC PATIENTS, BY COUNTRY, 2023–2030 (USD MILLION) 167

TABLE 144            MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET FOR PEDIATRIC PATIENTS, BY REGION, 2023–2030 (USD MILLION)            167

TABLE 145            COMPOUNDING PHARMACY MARKET, BY REGION, 2023–2030 (USD MILLION)          169

TABLE 146            NORTH AMERICA: KEY MACROINDICATORS                 171

TABLE 147            NORTH AMERICA: COMPOUNDING PHARMACY MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            172

TABLE 148            NORTH AMERICA: COMPOUNDING PHARMACY MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            172

TABLE 149            NORTH AMERICA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)                 173

TABLE 150            NORTH AMERICA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)            173

TABLE 151            NORTH AMERICA: COMPOUNDING PHARMACY MARKET, BY STERILITY,

2023–2030 (USD MILLION)            174

TABLE 152            NORTH AMERICA: COMPOUNDING PHARMACY MARKET, BY END USER,

2023–2030 (USD MILLION)            174

TABLE 153            US: COMPOUNDING PHARMACY MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            175

TABLE 154            US: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE,

2023–2030 (USD MILLION)            175

TABLE 155            US: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION,

2023–2030 (USD MILLION)            176

TABLE 156            US: COMPOUNDING PHARMACY MARKET, BY STERILITY,

2023–2030 (USD MILLION)            176

TABLE 157            US: COMPOUNDING PHARMACY MARKET, BY END USER,

2023–2030 (USD MILLION)            176

TABLE 158          CANADA: COMPOUNDING PHARMACY MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            177

TABLE 159          CANADA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE,

2023–2030 (USD MILLION)            178

TABLE 160          CANADA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)                 178

TABLE 161          CANADA: COMPOUNDING PHARMACY MARKET, BY STERILITY,

2023–2030 (USD MILLION)            179

TABLE 162          CANADA: COMPOUNDING PHARMACY MARKET, BY END USER,

2023–2030 (USD MILLION)            179

TABLE 163            EUROPE: KEY MACROINDICATORS          181

TABLE 164            EUROPE: COMPOUNDING PHARMACY MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            181

TABLE 165            EUROPE: COMPOUNDING PHARMACY MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            182

TABLE 166            EUROPE: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE,

2023–2030 (USD MILLION)            182

TABLE 167            EUROPE: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)                 183

TABLE 168            EUROPE: COMPOUNDING PHARMACY MARKET, BY STERILITY,

2023–2030 (USD MILLION)            183

TABLE 169            EUROPE: COMPOUNDING PHARMACY MARKET, BY END USER,

2023–2030 (USD MILLION)            183

TABLE 170            GERMANY: COMPOUNDING PHARMACY MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            184

TABLE 171            GERMANY: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE,

2023–2030 (USD MILLION)            185

TABLE 172            GERMANY: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)            185

TABLE 173            GERMANY: COMPOUNDING PHARMACY MARKET, BY STERILITY,

2023–2030 (USD MILLION)            186

TABLE 174            GERMANY: COMPOUNDING PHARMACY MARKET, BY END USER,

2023–2030 (USD MILLION)            186

TABLE 175            UK: COMPOUNDING PHARMACY MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            187

TABLE 176            UK: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE,

2023–2030 (USD MILLION)            187

TABLE 177            UK: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION,

2023–2030 (USD MILLION)            188

TABLE 178            UK: COMPOUNDING PHARMACY MARKET, BY STERILITY,

2023–2030 (USD MILLION)            188

TABLE 179            UK: COMPOUNDING PHARMACY MARKET, BY END USER,

2023–2030 (USD MILLION)            188

TABLE 180            FRANCE: COMPOUNDING PHARMACY MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            189

TABLE 181            FRANCE: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE,

2023–2030 (USD MILLION)            190

TABLE 182            FRANCE: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)                 190

TABLE 183            FRANCE: COMPOUNDING PHARMACY MARKET, BY STERILITY,

2023–2030 (USD MILLION)            191

TABLE 184            FRANCE: COMPOUNDING PHARMACY MARKET, BY END USER,

2023–2030 (USD MILLION)            191

TABLE 185            ITALY: COMPOUNDING PHARMACY MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            192

TABLE 186            ITALY: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE,

2023–2030 (USD MILLION)            192

TABLE 187            ITALY: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)                 193

TABLE 188            ITALY: COMPOUNDING PHARMACY MARKET, BY STERILITY,

2023–2030 (USD MILLION)            193

TABLE 189            ITALY: COMPOUNDING PHARMACY MARKET, BY END USER,

2023–2030 (USD MILLION)            193

TABLE 190            SPAIN: COMPOUNDING PHARMACY MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            194

TABLE 191            SPAIN: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE,

2023–2030 (USD MILLION)            195

TABLE 192            SPAIN: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)                 195

TABLE 193            SPAIN: COMPOUNDING PHARMACY MARKET, BY STERILITY,

2023–2030 (USD MILLION)            196

TABLE 194            SPAIN: COMPOUNDING PHARMACY MARKET, BY END USER,

2023–2030 (USD MILLION)            196

TABLE 195            REST OF EUROPE: COMPOUNDING PHARMACY MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            197

TABLE 196            REST OF EUROPE: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)                 197

TABLE 197            REST OF EUROPE: COMPOUNDING PHARMACY MARKET,

BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)                 198

TABLE 198            REST OF EUROPE: COMPOUNDING PHARMACY MARKET, BY STERILITY,

2023–2030 (USD MILLION)            198

TABLE 199            REST OF EUROPE: COMPOUNDING PHARMACY MARKET, BY END USER,

2023–2030 (USD MILLION)            199

TABLE 200            ASIA PACIFIC: KEY MACROINDICATORS                 201

TABLE 201            ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            201

TABLE 202            ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            202

TABLE 203            ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)                 202

TABLE 204            ASIA PACIFIC: COMPOUNDING PHARMACY MARKET,

BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)                 203

TABLE 205            ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY STERILITY,

2023–2030 (USD MILLION)            203

TABLE 206            ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY END USER,

2023–2030 (USD MILLION)            204

TABLE 207            CHINA: COMPOUNDING PHARMACY MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            204

TABLE 208            CHINA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE,

2023–2030 (USD MILLION)            205

TABLE 209            CHINA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)                 205

TABLE 210            CHINA: COMPOUNDING PHARMACY MARKET, BY STERILITY,

2023–2030 (USD MILLION)            206

TABLE 211            CHINA: COMPOUNDING PHARMACY MARKET, BY END USER,

2023–2030 (USD MILLION)            206

TABLE 212            JAPAN: COMPOUNDING PHARMACY MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            207

TABLE 213            JAPAN: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE,

2023–2030 (USD MILLION)            207

TABLE 214            JAPAN: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)                 208

TABLE 215            JAPAN: COMPOUNDING PHARMACY MARKET, BY STERILITY,

2023–2030 (USD MILLION)            208

TABLE 216            JAPAN: COMPOUNDING PHARMACY MARKET, BY END USER,

2023–2030 (USD MILLION)            208

TABLE 217            INDIA: COMPOUNDING PHARMACY MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            209

TABLE 218            INDIA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE,

2023–2030 (USD MILLION)            209

TABLE 219            INDIA: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)                 210

TABLE 220            INDIA: COMPOUNDING PHARMACY MARKET, BY STERILITY,

2023–2030 (USD MILLION)            210

TABLE 221            INDIA: COMPOUNDING PHARMACY MARKET, BY END USER,

2023–2030 (USD MILLION)            210

TABLE 222            AUSTRALIA: COMPOUNDING PHARMACY MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            211

TABLE 223            AUSTRALIA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE,

2023–2030 (USD MILLION)            212

TABLE 224            AUSTRALIA : COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)            212

TABLE 225            AUSTRALIA: COMPOUNDING PHARMACY MARKET, BY STERILITY,

2023–2030 (USD MILLION)            213

TABLE 226            AUSTRALIA: COMPOUNDING PHARMACY MARKET, BY END USER,

2023–2030 (USD MILLION)            213

TABLE 227            SOUTH KOREA: COMPOUNDING PHARMACY MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            214

TABLE 228            SOUTH KOREA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)                 214

TABLE 229            SOUTH KOREA: COMPOUNDING PHARMACY MARKET,

BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)                 215

TABLE 230            SOUTH KOREA: COMPOUNDING PHARMACY MARKET, BY STERILITY,

2023–2030 (USD MILLION)            215

TABLE 231            SOUTH KOREA: COMPOUNDING PHARMACY MARKET, BY END USER,

2023–2030 (USD MILLION)            216

TABLE 232            REST OF ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            216

TABLE 233            REST OF ASIA PACIFIC: COMPOUNDING PHARMACY MARKET,

BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)      217

TABLE 234            REST OF ASIA PACIFIC: COMPOUNDING PHARMACY MARKET,

BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)                 217

TABLE 235            REST OF ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY STERILITY,

2023–2030 (USD MILLION)            218

TABLE 236            REST OF ASIA PACIFIC: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)                 218

TABLE 237            LATIN AMERICA: KEY MACROINDICATORS                 219

TABLE 238            LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            220

TABLE 239            LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            220

TABLE 240            LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)                 221

TABLE 241            LATIN AMERICA: COMPOUNDING PHARMACY MARKET,

BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)                 221

TABLE 242            LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY STERILITY,

2023–2030 (USD MILLION)            222

TABLE 243            LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY END USER,

2023–2030 (USD MILLION)            222

TABLE 244            BRAZIL: COMPOUNDING PHARMACY MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            223

TABLE 245            BRAZIL: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE,

2023–2030 (USD MILLION)            223

TABLE 246            BRAZIL: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)                 224

TABLE 247            BRAZIL: COMPOUNDING PHARMACY MARKET, BY STERILITY,

2023–2030 (USD MILLION)            224

TABLE 248            BRAZIL: COMPOUNDING PHARMACY MARKET, BY END USER,

2023–2030 (USD MILLION)            224

TABLE 249            MEXICO: COMPOUNDING PHARMACY MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            225

TABLE 250            MEXICO: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE,

2023–2030 (USD MILLION)            226

TABLE 251            MEXICO: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)                 226

TABLE 252            MEXICO: COMPOUNDING PHARMACY MARKET, BY STERILITY,

2023–2030 (USD MILLION)            227

TABLE 253            MEXICO: COMPOUNDING PHARMACY MARKET, BY END USER,

2023–2030 (USD MILLION)            227

TABLE 254            REST OF LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)                 228

TABLE 255            REST OF LATIN AMERICA: COMPOUNDING PHARMACY MARKET,

BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)      228

TABLE 256            REST OF LATIN AMERICA: COMPOUNDING PHARMACY MARKET,

BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)                 229

TABLE 257            REST OF LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)                 229

TABLE 258            REST OF LATIN AMERICA: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)                 230

TABLE 259            MIDDLE EAST & AFRICA: KEY MACROINDICATORS      231

TABLE 260            MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY REGION,

2023–2030 (USD MILLION)            231

TABLE 261            MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2023–2030 (USD MILLION)                 232

TABLE 262            MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET,

BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)      232

TABLE 263            MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET,

BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)                 233

TABLE 264            MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY STERILITY, 2023–2030 (USD MILLION)                 233

TABLE 265            MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET, BY END USER, 2023–2030 (USD MILLION)                 234

TABLE 266            GCC COUNTRIES: COMPOUNDING PHARMACY MARKET, BY PRODUCT,

2023–2030 (USD MILLION)            235

TABLE 267            GCC COUNTRIES: COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)                 235

TABLE 268            GCC COUNTRIES: COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)            236

TABLE 269            GCC COUNTRIES: COMPOUNDING PHARMACY MARKET, BY STERILITY,

2023–2030 (USD MILLION)            236

TABLE 270            GCC COUNTRIES: COMPOUNDING PHARMACY MARKET, BY END USER,

2023–2030 (USD MILLION)            237

TABLE 271            REST OF MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET,

BY PRODUCT, 2023–2030 (USD MILLION)               238

TABLE 272            REST OF MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET,

BY COMPOUNDING TYPE, 2023–2030 (USD MILLION)      238

TABLE 273            REST OF MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET,

BY THERAPEUTIC APPLICATION, 2023–2030 (USD MILLION)                 239

TABLE 274            REST OF MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET,

BY STERILITY, 2023–2030 (USD MILLION)               239

TABLE 275            REST OF MIDDLE EAST & AFRICA: COMPOUNDING PHARMACY MARKET,

BY END USER, 2023–2030 (USD MILLION)               240

TABLE 276            OVERVIEW OF MAJOR STRATEGIES DEPLOYED BY KEY PLAYERS IN COMPOUNDING PHARMACY MARKET, 2023–2025        241

TABLE 277            COMPOUNDING PHARMACY MARKET: DEGREE OF COMPETITION           245

TABLE 278            COMPOUNDING PHARMACY MARKET: REGION FOOTPRINT       248

TABLE 279            COMPOUNDING PHARMACY MARKET: PRODUCT FOOTPRINT 249

TABLE 280            COMPOUNDING PHARMACY MARKET: THERAPEUTIC APPLICATION FOOTPRINT          250

TABLE 281            COMPOUNDING PHARMACY MARKET: STERILITY FOOTPRINT 250

TABLE 282            COMPOUNDING PHARMACY MARKET: DETAILED LIST OF

KEY STARTUP/SME PLAYERS      253

TABLE 283            COMPOUNDING PHARMACY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY PRODUCT, THERAPEUTIC APPLICATION,

AND REGION, 2024           254

TABLE 284            COMPOUNDING PHARMACY MARKET: PRODUCT LAUNCHES,

JANUARY 2022–OCTOBER 2025   257

TABLE 285            COMPOUNDING PHARMACY MARKET: DEALS, JANUARY 2022–OCTOBER 2025   258

TABLE 286            COMPOUNDING PHARMACY MARKET: EXPANSIONS,

JANUARY 2022–OCTOBER 2025   259

TABLE 287            BAXTER: COMPANY OVERVIEW 260

TABLE 288            BAXTER: PRODUCTS OFFERED 261

TABLE 289            BAXTER: PRODUCT LAUNCHES, JANUARY 2022–OCTOBER 2025  262

TABLE 290            EMPOWER PHARMACY: COMPANY OVERVIEW                 263

TABLE 291            EMPOWER PHARMACY: PRODUCTS OFFERED                 263

TABLE 292            EMPOWER PHARMACY: EXPANSIONS, JANUARY 2022–OCTOBER 2025        265

TABLE 293            B. BRAUN SE: COMPANY OVERVIEW       266

TABLE 294            B. BRAUN SE: PRODUCTS OFFERED        267

TABLE 295            B. BRAUN SE: PRODUCT LAUNCHES, JANUARY 2022–OCTOBER 2025        268

TABLE 296            FAGRON: COMPANY OVERVIEW                269

TABLE 297            FAGRON: PRODUCTS OFFERED 270

TABLE 298            FAGRON: DEALS, JANUARY 2022–OCTOBER 2025                 271

TABLE 299            QUVA PHARMA, INC.: COMPANY OVERVIEW                 273

TABLE 300            QUVA PHARMA, INC.: PRODUCTS OFFERED                 273

TABLE 301            SCA PHARMA: COMPANY OVERVIEW      276

TABLE 302            SCA PHARMA: PRODUCTS OFFERED       276

TABLE 303            SCA PHARMA: DEALS, JANUARY 2022–OCTOBER 2025        277

TABLE 304            NEPHRON PHARMACEUTICALS: COMPANY OVERVIEW          278

TABLE 305            NEPHRON PHARMACEUTICALS: PRODUCTS OFFERED             278

TABLE 306            NEPHRON PHARMACEUTICALS: EXPANSIONS, JANUARY 2022–OCTOBER 2025   279

TABLE 307            LEITERS HEALTH: COMPANY OVERVIEW                 280

TABLE 308            LEITERS HEALTH: PRODUCTS OFFERED                 280

TABLE 309            LEITERS HEALTH: EXPANSIONS, JANUARY 2022–OCTOBER 2025  281

TABLE 310            ICON GROUP: COMPANY OVERVIEW      282

TABLE 311            ICON GROUP: PRODUCTS OFFERED       282

TABLE 312            ICON GROUP: DEALS, JANUARY 2022–OCTOBER 2025        283

TABLE 313            ROSEWAY LABS: COMPANY OVERVIEW 284

TABLE 314            ROSEWAY LABS: PRODUCTS OFFERED  284

TABLE 315            ROSEWAY LABS: OTHER DEVELOPMENTS, JANUARY 2022–OCTOBER 2025   285

TABLE 316            ITH PHARMA: COMPANY OVERVIEW      286

TABLE 317            ITH PHARMA: PRODUCTS OFFERED       286

TABLE 318            PENCOL COMPOUNDING PHARMACY: COMPANY OVERVIEW   287

TABLE 319            PENCOL COMPOUNDING PHARMACY: PRODUCTS OFFERED    287

TABLE 320            FORMUL8: COMPANY OVERVIEW             288

TABLE 321            FORMUL8: PRODUCTS OFFERED              288

TABLE 322            AURORA COMPOUNDING PHARMACY: COMPANY OVERVIEW   289

TABLE 323            AURORA COMPOUNDING PHARMACY: PRODUCTS OFFERED    289

TABLE 324            CUSTOM MED APOTHECARY: COMPANY OVERVIEW          290

TABLE 325            INSTITUTIONAL PHARMACY SOLUTIONS: COMPANY OVERVIEW   291

TABLE 326            FUSION APOTHECARY: COMPANY OVERVIEW                 291

TABLE 327            INNOVATION COMPOUNDING PHARMACY: COMPANY OVERVIEW   292

TABLE 328            RX3 COMPOUNDING PHARMACY: COMPANY OVERVIEW          292

TABLE 329            DOUGHERTY’S PHARMACY, INC.: COMPANY OVERVIEW          293

TABLE 330            LORRAINE’S PHARMACY: COMPANY OVERVIEW                 293

TABLE 331            WELLS PHARMA: COMPANY OVERVIEW                 294

TABLE 332            OLYMPIA PHARMACY: COMPANY OVERVIEW                 294

TABLE 333            FRESH THERAPEUTICS: COMPANY OVERVIEW                 295

TABLE 334            MEDIOS AG: COMPANY OVERVIEW         296

LIST OF FIGURES

FIGURE 1              COMPOUNDING PHARMACY MARKET SEGMENTATION & REGIONAL SCOPE    32

FIGURE 2              COMPOUNDING PHARMACY MARKET: YEARS CONSIDERED    33

FIGURE 3              COMPOUNDING PHARMACY MARKET: RESEARCH DESIGN         35

FIGURE 4              COMPOUNDING PHARMACY MARKET: KEY DATA FROM SECONDARY SOURCES        37

FIGURE 5              COMPOUNDING PHARMACY MARKET: BREAKDOWN OF PRIMARY INTERVIEWS               38

FIGURE 6              COMPOUNDING PHARMACY MARKET SIZE ESTIMATION

(SUPPLY-SIDE ANALYSIS), 2024  39

FIGURE 7              COMPANY REVENUE ANALYSIS-BASED ESTIMATION: BOTTOM-UP APPROACH (2024)   40

FIGURE 8              REVENUE SHARE ANALYSIS OF BAXTER (2024)                 40

FIGURE 9              COMPOUNDING PHARMACY MARKET SIZE VALIDATION FROM PRIMARY SOURCES                41

FIGURE 10            COMPOUNDING PHARMACY MARKET: TOP-DOWN APPROACH          42

FIGURE 11            COMPOUNDING PHARMACY MARKET: CAGR PROJECTIONS   44

FIGURE 12            COMPOUNDING PHARMACY MARKET: DATA TRIANGULATION             46

FIGURE 13            COMPOUNDING PHARMACY MARKET, BY PRODUCT,

2025 VS. 2030 (USD MILLION)      50

FIGURE 14            COMPOUNDING PHARMACY MARKET, BY COMPOUNDING TYPE,

2025 VS. 2030 (USD MILLION)      51

FIGURE 15            COMPOUNDING PHARMACY MARKET, BY THERAPEUTIC APPLICATION,

2025 VS. 2030 (USD MILLION)      51

FIGURE 16            COMPOUNDING PHARMACY MARKET, BY END USER,

2025 VS. 2030 (USD MILLION)      52

FIGURE 17            REGIONAL SNAPSHOT OF COMPOUNDING PHARMACY MARKET      53

FIGURE 18            RISING TREND OF PERSONALISED MEDICINES TO PROPEL MARKET GROWTH 54

FIGURE 19            US AND 0RAL DRUGS SEGMENT TO COMMAND LARGEST SHARE

OF NORTH AMERICAN MARKET IN 2025                 55

FIGURE 20            INDIA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD         56

FIGURE 21            EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES

DURING STUDY PERIOD               57

FIGURE 22           COMPOUNDING PHARMACY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES         60

FIGURE 23            TOTAL PRESCRIPTION DRUG SALES, 2023–2030 (USD BILLION) 63

FIGURE 24            COMPOUNDING PHARMACY MARKET: PORTER’S FIVE FORCES ANALYSIS           67

FIGURE 25            INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF KEY COMPOUNDING PHARMACY PRODUCTS         69

FIGURE 26            KEY BUYING CRITERIA FOR COMPOUNDING PHARMACY PRODUCTS, BY END USER  71

FIGURE 27            GLOBAL PHARMACEUTICAL R&D EXPENDITURE, 2023–2030 (USD BILLION)             75

FIGURE 28            COMPOUNDING PHARMACY MARKET: VALUE CHAIN ANALYSIS              76

FIGURE 29            COMPOUNDING PHARMACY MARKET: ECOSYSTEM MAP             77

FIGURE 30            TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES IN COMPOUNDING PHARMACY MARKET               82

FIGURE 31            INVESTMENT AND NUMBER OF DEALS IN COMPOUNDING PHARMACY MARKET, 2023–2025 (USD MILLION)            82

FIGURE 32            COMPOUNDING PHARMACY MARKET: IMPACT OF AI/GEN AI     85

FIGURE 33            NORTH AMERICA: COMPOUNDING PHARMACY MARKET SNAPSHOT       170

FIGURE 34            ASIA PACIFIC: COMPOUNDING PHARMACY MARKET SNAPSHOT       200

FIGURE 35            REVENUE ANALYSIS OF KEY PLAYERS IN COMPOUNDING PHARMACY MARKET, 2022–2024 (USD MILLION)            243

FIGURE 36            MARKET SHARE ANALYSIS OF KEY PLAYERS IN COMPOUNDING PHARMACY MARKET (2024)      244

FIGURE 37            COMPOUNDING PHARMACY MARKET: COMPANY EVALUATION MATRIX

(KEY PLAYERS), 2024       247

FIGURE 38            COMPOUNDING PHARMACY MARKET: COMPANY FOOTPRINT 248

FIGURE 39            COMPOUNDING PHARMACY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024                 252

FIGURE 40            EV/EBITDA OF KEY VENDORS   255

FIGURE 41            YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK

BETA OF KEY VENDORS                255

FIGURE 42            COMPOUNDING PHARMACY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS     256

FIGURE 43            BAXTER: COMPANY SNAPSHOT (2024)   261

FIGURE 44            B. BRAUN SE: COMPANY SNAPSHOT (2024)                 267

FIGURE 45            FAGRON: COMPANY SNAPSHOT (2024)  270

MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
• 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
• ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11

MarketsandMarkets  出版レポート一覧